Avi Ashkenazi

List of Publications by Citations

Source: https://exaly.com/author-pdf/5693433/avi-ashkenazi-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160 33,634 83 183 h-index g-index citations papers 35,841 184 7.26 14.8 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
160	Death receptors: signaling and modulation. <i>Science</i> , 1998 , 281, 1305-8	33.3	4373
159	Safety and antitumor activity of recombinant soluble Apo2 ligand. <i>Journal of Clinical Investigation</i> , 1999 , 104, 155-62	15.9	1732
158	Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. <i>Science</i> , 1997 , 277, 818-21	33.3	1483
157	Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry, 1996 , 271, 12687-90	5.4	1384
156	Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology, 1999, 11, 255-60	9	1113
155	Targeting death and decoy receptors of the tumour-necrosis factor superfamily. <i>Nature Reviews Cancer</i> , 2002 , 2, 420-30	31.3	1092
154	Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. <i>Immunity</i> , 2000 , 12, 611-20	32.3	830
153	Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation, 2003, 10, 66-75	12.7	726
152	Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. <i>Nature</i> , 1998 , 396, 699-703	50.4	658
151	Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. <i>Nature Medicine</i> , 2001 , 7, 383-5	50.5	641
150	Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. <i>Nature</i> , 1988 , 334, 434-7	50.4	632
149	A novel receptor for Apo2L/TRAIL contains a truncated death domain. <i>Current Biology</i> , 1997 , 7, 1003-6	6.3	569
148	Primary structure and biochemical properties of an M2 muscarinic receptor. <i>Science</i> , 1987 , 236, 600-5	33.3	497
147	Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. <i>Cell</i> , 2009 , 137, 721-35	56.2	484
146	Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. <i>Nature Medicine</i> , 2007 , 13, 1070-7	50.5	477
145	From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 273-284	64.1	467
144	Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. <i>Cytokine and Growth Factor Reviews</i> , 2003 , 14, 337-48	17.9	466

143	Tumor-cell resistance to death receptorinduced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. <i>Nature Medicine</i> , 2002 , 8, 274-81	50.5	458
142	Tumor necrosis factor: an apoptosis JuNKie?. <i>Cell</i> , 2004 , 116, 491-7	56.2	434
141	Death receptor signal transducers: nodes of coordination in immune signaling networks. <i>Nature Immunology</i> , 2009 , 10, 348-55	19.1	416
140	Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. <i>Science</i> , 2014 , 345, 98-101	33.3	378
139	Pharmacological brake-release of mRNA translation enhances cognitive memory. <i>ELife</i> , 2013 , 2, e00498	8.9	377
138	Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. <i>Journal of Biological Chemistry</i> , 2001 , 276, 46639-46	5.4	373
137	An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. <i>Science</i> , 1987 , 238, 672-5	33.3	367
136	Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. <i>Molecular Cell</i> , 1999 , 4, 563-71	17.6	360
135	Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). <i>Journal of Clinical Oncology</i> , 2008 , 26, 3621-30	2.2	355
134	Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. <i>Current Biology</i> , 2000 , 10, 785-8	6.3	347
133	Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2839-46	2.2	346
132	Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 1001-12	64.1	331
131	Targeting the extrinsic apoptosis pathway in cancer. Cytokine and Growth Factor Reviews, 2008, 19, 325-	• 3 †.9	319
130	Targeting death receptors in cancer with Apo2L/TRAIL. Current Opinion in Pharmacology, 2004, 4, 333-9	5.1	312
129	New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene, 2010, 29, 4752-65	9.2	280
128	A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. <i>Nature</i> , 1992 , 360, 161-3	50.4	273
127	Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell. <i>Cell</i> , 1989 , 56, 487-93	56.2	265
126	Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of Virology 1992, 66, 235-43	6.6	248

125	Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. <i>Journal of Biological Chemistry</i> , 1997 , 272, 14029-32	5.4	247
124	To kill a tumor cell: the potential of proapoptotic receptor agonists. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1979-90	15.9	247
123	Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. <i>Nature</i> , 1989 , 340, 146-50	50.4	239
122	A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. <i>Biochemistry</i> , 2000 , 39, 633-40	3.2	233
121	Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. <i>Current Biology</i> , 1996 , 6, 1669-76	6.3	231
120	Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 10535-9	11.5	228
119	NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-Ifeedforward signaling. <i>Cell</i> , 2011 , 145, 92-103	56.2	215
118	Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. <i>Journal of Biological Chemistry</i> , 2005 , 280, 2205-12	5.4	215
117	An FcTreceptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. <i>Cancer Cell</i> , 2011 , 19, 101-13	24.3	206
116	Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. <i>Journal of Biological Chemistry</i> , 2005 , 280, 40599-608	5.4	203
115	Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. <i>Oncogene</i> , 2008 , 27, 85-97	9.2	202
114	Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. <i>Nature Immunology</i> , 2000 , 1, 37-41	19.1	195
113	Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. <i>Journal of Immunology</i> , 2001 , 166, 4891-8	5.3	192
112	Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4442-51	2.2	191
111	Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 265, 479-83	3.4	188
110	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1216-29	15.9	185
109	Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. <i>Current Biology</i> , 1996 , 6, 750-2	6.3	184
108	TWEAK attenuates the transition from innate to adaptive immunity. <i>Cell</i> , 2005 , 123, 931-44	56.2	180

(2006-2001)

107	TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. <i>Nature Immunology</i> , 2001 , 2, 632-7	19.1	178
106	Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. <i>Science</i> , 1995 , 270, 1215-8	33.3	177
105	Identification of a ligand for the death-domain-containing receptor Apo3. Current Biology, 1998, 8, 525-	8 6.3	172
104	Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. <i>Current Biology</i> , 1999 , 9, 215-8	6.3	168
103	Regulated cell death: signaling and mechanisms. <i>Annual Review of Cell and Developmental Biology</i> , 2014 , 30, 337-56	12.6	167
102	APRIL-deficient mice have normal immune system development. <i>Molecular and Cellular Biology</i> , 2004 , 24, 997-1006	4.8	158
101	Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. <i>Journal of Clinical Investigation</i> , 2015 , 125, 487-9	15.9	154
100	Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 7150-4	11.5	152
99	APO2 ligand: a novel lethal weapon against malignant glioma?. FEBS Letters, 1998, 427, 124-8	3.8	145
98	Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. <i>PLoS ONE</i> , 2012 , 7, e36	7 1.3	143
97	The MHC-binding and gp120-binding functions of CD4 are separable. <i>Science</i> , 1989 , 245, 743-6	33.3	140
96	A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2010 , 16, 1256-63	12.9	136
95	Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. <i>Cell Death and Differentiation</i> , 2008 , 15, 751-61	12.7	125
94	Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. <i>Journal of Biological Chemistry</i> , 2005 , 280, 1940	1 ^{.594}	120
93	Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. <i>Molecular and Cellular Biology</i> , 1996 , 16, 3214-21	4.8	117
92	Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. <i>Current Opinion in Cell Biology</i> , 2010 , 22, 837-44	9	115
91	TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. <i>Molecular Cell</i> , 2012 , 48, 888-99	17.6	110
90	Functional characterization of the Bcl-2 gene family in the zebrafish. <i>Cell Death and Differentiation</i> , 2006 , 13, 1631-40	12.7	107

89	Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. <i>Cancer Research</i> , 2004 , 64, 4900-5	10.1	106
88	AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Research, 2014, 74, 58	78 1 901	101
87	Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. <i>PLoS ONE</i> , 2007 , 2, e575	3.7	98
86	The zebrafish as a model organism for the study of apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010 , 15, 331-49	5.4	97
85	Death-receptor activation halts clathrin-dependent endocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 10283-10288	11.5	95
84	Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. <i>Blood</i> , 2007 , 110, 4037-46	2.2	91
83	Immunoadhesins: principles and applications. <i>Trends in Biotechnology</i> , 1996 , 14, 52-60	15.1	89
82	Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 7056-60	11.5	89
81	Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. <i>Journal of Biological Chemistry</i> , 1993 , 268, 26059-62	5.4	89
80	Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. <i>Cell Death and Differentiation</i> , 2006 , 13, 1619-30	12.7	87
79	Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. <i>Scandinavian Journal of Immunology</i> , 2000 , 51, 244-50	3.4	84
78	Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 5401-5	11.5	83
77	Binding sites of human growth hormone and ovine and bovine prolactins in the mammary gland and the liver of lactating dairy cow. <i>Molecular and Cellular Endocrinology</i> , 1984 , 34, 51-7	4.4	76
76	Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate. <i>Molecular Cell</i> , 2018 , 71, 629-636.e5	17.6	75
75	E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. <i>Molecular Cell</i> , 2014 , 54, 987-98	17.6	73
74	Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. <i>Cytokine</i> , 1999 , 11, 664-72	4	73
73	ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. <i>Immunology and Cell Biology</i> , 2012 , 90, 540-52	5	70
72	TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. <i>Journal of Biological Chemistry</i> , 2011 , 286, 21546-54	5.4	69

71	Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1245-54	6.1	65	
70	Immunoadhesins as research tools and therapeutic agents. <i>Current Opinion in Immunology</i> , 1997 , 9, 195	5-27080	65	
69	Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. <i>Cancer Research</i> , 2004 , 64, 9105-14	10.1	65	
68	Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. <i>American Journal of Pathology</i> , 2002 , 161, 643-54	5.8	63	
67	Apoptosis initiation through the cell-extrinsic pathway. <i>Methods in Enzymology</i> , 2014 , 544, 99-128	1.7	58	
66	FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. <i>Cancer Research</i> , 2012 , 72, 5843-55	10.1	58	
65	Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 5679-84	11.5	55	
64	Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. <i>Journal of Immunology</i> , 2014 , 192, 3259-68	5.3	53	
63	TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. <i>Immunology and Cell Biology</i> , 2005 , 83, 511-9	5	53	
62	TRAF2 is a biologically important necroptosis suppressor. <i>Cell Death and Differentiation</i> , 2015 , 22, 1846	5- 57 .7	51	
61	X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. <i>Journal of Biological Chemistry</i> , 2009 , 284, 34553-60	5.4	50	
60	Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. <i>Cancer Cell</i> , 2012 , 22, 80-90	24.3	49	
59	Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. <i>Clinical Cancer Research</i> , 2008 , 14, 7733-40	12.9	49	
58	Design, construction, and in vitro analyses of multivalent antibodies. <i>Journal of Immunology</i> , 2003 , 170, 4854-61	5.3	49	
57	Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2541-6	6.1	47	
56	Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. <i>Biochemistry</i> , 1993 , 32, 3131-8	3.2	46	
55	Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. Journal of Molecular Biology, 2006 , 361, 522-36	6.5	43	
54	A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 248-54	3.8	42	

53	Immunoadhesins. International Reviews of Immunology, 1993, 10, 219-27	4.6	42
52	Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH. <i>Endocrinology</i> , 1986 , 118, 720-6	4.8	41
51	Disruption of IRE1Ithrough its kinase domain attenuates multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16420-16429	11.5	40
50	Snapshot: caspases. <i>Cell</i> , 2011 , 147, 476-476.e1	56.2	39
49	Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation. <i>Bioconjugate Chemistry</i> , 1994 , 5, 133-40	6.3	39
48	Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. <i>ELife</i> , 2020 , 9,	8.9	37
47	Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2599-608	6.1	36
46	Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. <i>Clinical Cancer Research</i> , 2010 , 16, 1587-96	12.9	34
45	Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. <i>Journal of Infectious Diseases</i> , 1994 , 170, 1323-6	7	34
44	Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. <i>Biochemistry</i> , 1990 , 29, 9885-91	3.2	34
43	Fclreceptors enable anticancer action of proapoptotic and immune-modulatory antibodies. Journal of Experimental Medicine, 2013 , 210, 1647-51	16.6	30
42	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. <i>Lancet Haematology,the</i> , 2015 , 2, e166-74	14.6	29
41	Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. <i>Gene Therapy</i> , 2007 , 14, 147-61	4	26
40	Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994 , 1194, 185	- 36 8	26
39	Complementary proteomic tools for the dissection of apoptotic proteolysis events. <i>Journal of Proteome Research</i> , 2012 , 11, 2947-54	5.6	23
38	Comparative study of in vitro and in vivo modulation of lactogenic and somatotropic receptors by native human growth hormone and its modified analog prepared by recombinant deoxyribonucleic acid technology. <i>Endocrinology</i> , 1987 , 121, 414-9	4.8	22
37	Confirming a critical role for death receptor 5 and caspase-8 in apoptosis induction by endoplasmic reticulum stress. <i>Cell Death and Differentiation</i> , 2018 , 25, 1530-1531	12.7	21
36	Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. <i>Journal of Clinical Investigation</i> , 1995 , 95, 1947-52	15.9	21

(2020-2019)

35	Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. <i>ELife</i> , 2019 , 8,	8.9	20
34	Is SIRT2 required for necroptosis?. <i>Nature</i> , 2014 , 506, E4-6	50.4	19
33	Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. <i>Journal of Biological Chemistry</i> , 2011 , 286, 32762-74	5.4	19
32	ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 15-22	2.1	18
31	Characterization of lactogen receptors in lactogenic hormone-dependent and independent NB2 lymphoma cell lines. <i>FEBS Letters</i> , 1987 , 210, 51-5	3.8	18
30	MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 6324-35	12.9	17
29	Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. <i>Immunology and Cell Biology</i> , 2013 , 91, 451-60	5	16
28	Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. <i>Molecular Immunology</i> , 1994 , 31, 1335-44	4.3	15
27	Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-O-tetradecanoyl-phorbol-13-acetate. <i>Journal of Cellular Biochemistry</i> , 1988 , 37, 119-29	4.7	15
26	The third intracellular loop of the 5-hydroxytryptamine2A receptor determines effector coupling specificity. <i>Journal of Neurochemistry</i> , 1995 , 64, 1440-7	6	14
25	Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. <i>Cell Death and Disease</i> , 2016 , 7, e2338	9.8	13
24	Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. <i>MAbs</i> , 2019 , 11, 996-1011	6.6	12
23	Partial purification and characterization of bovine mammary gland prolactin receptor. <i>Molecular and Cellular Endocrinology</i> , 1987 , 50, 79-87	4.4	12
22	Immunoadhesins: An Alternative to Human Monoclonal Antibodies. <i>Methods</i> , 1995 , 8, 104-115	4.6	11
21	Molecular and biological properties of an interleukin-1 receptor immunoadhesin. <i>Molecular Immunology</i> , 1994 , 31, 1345-51	4.3	11
20	IRE1Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment. <i>Cancer Research</i> , 2020 , 80, 2368-2379	10.1	11
19	FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. <i>Cancer Biology and Therapy</i> , 2013 , 14, 711-9	4.6	10
18	Activation of the IRE1 RNase through remodeling of the kinase front pocket by ATP-competitive ligands. <i>Nature Communications</i> , 2020 , 11, 6387	17.4	8

17	MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. <i>EBioMedicine</i> , 2015 , 2, 406-20	8.8	7
16	A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. <i>Stem Cells and Development</i> , 1995 , 4, 439-46		6
15	Solubilization and characterization of lactogenic hormone receptor from kidney of lactating cow. <i>Molecular and Cellular Endocrinology</i> , 1989 , 61, 77-85	4.4	6
14	Uncovering a Dual Regulatory Role for Caspases During Endoplasmic Reticulum Stress-induced Cell Death. <i>Molecular and Cellular Proteomics</i> , 2016 , 15, 2293-307	7.6	6
13	Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2270-8	6.1	5
12	The stress-sensing domain of activated IRE1Iforms helical filaments in narrow ER membrane tubes. <i>Science</i> , 2021 , 374, 52-57	33.3	5
11	A comparative study of lactogenic hormone binding sites in the adrenal gland, ovary and kidney of the lactating cow. <i>Journal of Receptors and Signal Transduction</i> , 1987 , 7, 921-36		4
10	Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1 Nature Communications, 2021 , 12, 7310	17.4	4
9	Designer proteins to trigger cell death. <i>Cell</i> , 2014 , 157, 1506-8	56.2	3
8	UNCovering the molecular machinery of dependence receptor signaling. <i>Molecular Cell</i> , 2010 , 40, 851-3	17.6	3
7	Noncanonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1[promotes cancer-cell surviv	/al	3
6	Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1Inhibitory Activity. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 2389-2396	4.3	2
5	Membrane display and functional analysis of juxtacrine ligand-receptor signaling. <i>BioTechniques</i> , 2015 , 59, 231-8, 240	2.5	1
4	Combining enhanced metabolic labeling with immunoblotting to detect interactions of endogenous cellular proteins. <i>BioTechniques</i> , 2000 , 29, 506-10, 512	2.5	1
3	Pumilio protects Xbp1 mRNA from regulated Ire1-dependent decay <i>Nature Communications</i> , 2022 , 13, 1587	17.4	1
2	Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma <i>Science Translational Medicine</i> , 2022 , 14, eabl8146	17.5	1

Response to Recreted IgM versus BLyS in germinal center formation RNature Immunology, 2000, 1, 179 19.1